|(S)-4-(4-((2-(3,5-二甲基苯基)吡咯烷-1-基)甲基)苯氧基)-间氟苯甲酰胺|CsnPharm

CAS No.: 1174130-61-0

Synonyms: CERC-501;LY-2456302;CREC-501

LY-2456302 is a potent and centrally-penetrant kappa opioid receptor antagonist with a Ki of 0.807 nM.

规格	价格	促销价格	库存	数量

400-920-2911

加入购物车大规格询价

产品咨询

400-920-2911

纯度 & 质量文件批次:

生物活性

描述LY-2456302 is a potent and centrally-penetrant kappa opioid receptor antagonist with a Ki of 0.807 nM.
临床研究

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点
NCT01232439	Alcohol Dependence	Phase 1	Completed	-	United States, Connecticut ... more >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. New Haven, Connecticut, United States, 06519 Collapse <<
NCT02218736	ANXIETY DISORDERS (or Anxiety ... more >>and Phobic Neuroses) Collapse <<	Phase 2	Completed	-	United States, Connecticut ... more >> Yale University New Haven, Connecticut, United States, 06510 United States, Indiana Andrew Goddard, MD Indianapolis, Indiana, United States, 46202-l7176 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio CaseWestern Reserve University Cleveland, Ohio, United States, 44106 United States, Texas Baylor College of Medicine Houston, Texas, United States, 70030 Collapse <<
NCT02218775	Anxiety Disorders	Phase 1	Withdrawn(Funding for the stud... more >>y ended with one subject consented, but not randomized) Collapse <<	-	United States, Connecticut ... more >> Yale University New Haven, Connecticut, United States, 06510 Collapse <<

实验方案

技术信息

CAS号	1174130-61-0	储存条件	粉末 Keep in dark place,Inert atmosphere,Room temperature 液体 -20°C:3-6 月 -80°C:12月
分子式	C26H27FN2O2	运输	蓝冰
分子量	418.50	别名	CERC-501;LY-2456302;CREC-501;Opra Kappa;JNJ-67953964

大规格询价

号为必填项

姓名: 邮箱: 手机号:

留言:

提交

NCT号	适应症或疾病	临床期	招募状态	预计完成时间	地点

NCT01232439	Alcohol Dependence	Phase 1	Completed	-	United States, Connecticut ... more >> For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician. New Haven, Connecticut, United States, 06519 Collapse <<
NCT02218736	ANXIETY DISORDERS (or Anxiety ... more >>and Phobic Neuroses) Collapse <<	Phase 2	Completed	-	United States, Connecticut ... more >> Yale University New Haven, Connecticut, United States, 06510 United States, Indiana Andrew Goddard, MD Indianapolis, Indiana, United States, 46202-l7176 United States, New York Icahn School of Medicine at Mount Sinai New York, New York, United States, 10029 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Ohio CaseWestern Reserve University Cleveland, Ohio, United States, 44106 United States, Texas Baylor College of Medicine Houston, Texas, United States, 70030 Collapse <<
NCT02218775	Anxiety Disorders	Phase 1	Withdrawn(Funding for the stud... more >>y ended with one subject consented, but not randomized) Collapse <<	-	United States, Connecticut ... more >> Yale University New Haven, Connecticut, United States, 06510 Collapse <<

请登录您的专属账户